No Vaccine, No Approved Treatment: How the Bundibugyo Ebola Outbreak Became a Global Emergency in Eight Days

On May 15, 2026, the Democratic Republic of Congo confirmed an outbreak of Ebola disease in its northeastern Ituri Province caused by an uncommon strain: Bundibugyo ebolavirus [1]. Two days later, the World Health Organization declared it a Public Health Emergency of International Concern — the organization's highest alert level [2]. By May 23, Uganda had confirmed five cases of its own, Africa CDC had warned that 10 additional countries were at risk, and the outbreak had become the third-largest Ebola emergency on record, with more than 746 suspected cases and 176 suspected deaths in DRC alone [3][4].

What distinguishes this outbreak from the Ebola emergencies of 2014 and 2018 is a single, consequential fact: there is no approved vaccine and no licensed therapeutic for Bundibugyo virus [5][6].

The Numbers So Far

As of May 23, 2026, the WHO and DRC Ministry of Health reported 746 suspected cases and 176 suspected deaths in DRC, alongside 88 confirmed cases — 83 in DRC and 5 in Uganda — with 10 confirmed deaths, yielding a confirmed case fatality rate of approximately 12% [3][7]. Four healthcare workers died in the outbreak's first week [2].

Source: WHO Situation Reports

Data as of May 23, 2026CSV

The case fatality rate among confirmed cases is lower than the 30–50% historically associated with Bundibugyo virus disease and far below the roughly 40% rate of the 2014–2016 West Africa outbreak, which killed 11,325 people [8]. But the confirmed case count almost certainly understates the true toll: the ratio of 746 suspected cases to 88 confirmed cases suggests that laboratory capacity has not kept pace with the outbreak's spread. The WHO IHR Emergency Committee noted that the GeneXpert platform — widely used across DRC — cannot detect Bundibugyo virus, requiring RT-PCR testing that is available at fewer facilities [9].

Source: WHO / CDC Historical Data

Data as of May 24, 2026CSV

How the Virus Crossed the Border

The outbreak's index cases were identified in Ituri Province, a region that has experienced intensifying armed conflict since late 2025, with more than 100,000 people newly displaced and 273,403 internally displaced people overall [10]. Ituri sits directly on the Ugandan border, functions as a commercial and migratory hub, and sees heavy cross-border traffic driven by trade, mining, and displacement [11].

The first Ugandan case was a Congolese man who traveled from Ituri to Kampala, where he died [3]. Subsequent cases in Uganda have included healthcare workers and additional travelers returning from Ituri Province [7]. The WHO noted that a health worker in Bunia, the capital of Ituri, developed fever and hemorrhagic symptoms on April 24 — more than three weeks before the outbreak was officially declared — and died, raising questions about whether earlier detection could have contained the outbreak before it crossed international borders [10].

The DRC has 5.2 million internally displaced persons, the fourth-highest figure globally according to UNHCR data [12]. That displacement, combined with insecurity and porous borders, created conditions for spread that border screening alone could not prevent.

Source: UNHCR Population Data

Data as of Dec 31, 2025CSV

Ten Countries at Risk

On May 23, Africa CDC designated 10 countries beyond DRC and Uganda as "at risk": Angola, Burundi, the Central African Republic, the Republic of Congo, Ethiopia, Kenya, Rwanda, South Sudan, Tanzania, and Zambia [4][13]. With the exception of Ethiopia, all share a land border with either DRC or Uganda.

The designation was based on several factors: proximity to the outbreak's origin, the volume of cross-border population movement and trade, surveillance capacity gaps, and the presence of mining-related migration routes linking affected areas to neighboring states [14]. Africa CDC Director-General Jean Kaseya stated that "this outbreak started in Ituri and has now spread to Uganda and other regions in DRC, including South and North Kivu. This puts countries neighbouring DRC at risk" [13].

Kenya, which does not border DRC directly but has extensive trade and transport links with Uganda, identified 22 high-risk counties and activated emergency operations centers. Kenyan authorities trained more than 880 healthcare workers in Ebola response and designated four laboratories for testing [13].

Rwanda and South Sudan, both sharing borders with active outbreak zones, have been prioritized for preparedness support. Africa CDC deployed multidisciplinary teams covering epidemiology, infection prevention, laboratory systems, and logistics to both countries [14].

The Vaccine Gap

The defining challenge of this outbreak is the absence of medical countermeasures. Ervebo (rVSV-ZEBOV), the only licensed Ebola vaccine, targets the Zaire ebolavirus glycoprotein and has demonstrated 84–97.5% effectiveness against Zaire strains during outbreaks in Guinea and DRC [15][16]. It does not protect against Bundibugyo virus.

The two-dose Ad26.ZEBOV/MVA-BN-Filo regimen (marketed as Zabdeno/Mvabea) is also Zaire-specific [5]. Merck discontinued development of an rVSV-based vaccine for Sudan ebolavirus, and no manufacturer has advanced a Bundibugyo-specific candidate to late-stage trials [15].

The WHO IHR Emergency Committee acknowledged this gap directly: "Unlike Ebola virus causing Ebola virus disease, there is no currently approved therapeutics or vaccines against Bundibugyo virus." Candidate vaccines and therapeutics are under evaluation for clinical trials, but none are available for deployment in the current emergency [9].

This leaves the response dependent on the same public health measures that predated the vaccine era: contact tracing, 21-day monitoring of contacts, isolation and treatment centers providing intensive supportive care, safe and dignified burials, and community engagement through trusted local leaders [6][9].

Médecins Sans Frontières (MSF) described the Bundibugyo strain as posing a fundamentally different challenge from recent Ebola outbreaks. "Unlike for Ebola-zaire strains, there are currently no approved Bundibugyo virus-specific therapeutics or vaccines," the organization noted, adding that "early supportive care is lifesaving" but that health facilities in parts of DRC "have almost no protective equipment left for workers to use safely" [6][17].

Funding: Pledges vs. Reality

The financial response has been fragmented. WHO released $500,000 from its emergency fund and subsequently approved an additional $3.4 million from the Contingency Fund for Emergencies, bringing its total to $3.9 million [18][19]. Africa CDC internally mobilized $2 million [14]. The European Commission contributed €7.4 million through a contribution agreement with WHO for research and development [18].

On May 23, the U.S. State Department announced funding for up to 50 Ebola response clinics in affected regions of DRC and Uganda [20]. The total dollar figure was not immediately specified, though it represents a commitment to "enable implementing partners to establish clinical care and containment perimeters around affected areas" [20].

Africa CDC has estimated that its continental response requires $319 million but has received only $30 million from African member states — a shortfall of more than 90% [14]. By comparison, the 2014–2016 West Africa outbreak eventually attracted more than $3.6 billion in international funding, though much of that arrived months or years after the peak of the crisis.

The funding picture is complicated by recent structural changes to the U.S. global health apparatus.

The USAID Question

The Trump administration's restructuring of U.S. global health agencies has become a central point of contention. The changes are fourfold: withdrawal from WHO, dissolution of USAID, cutbacks at the CDC, and reductions in total health aid to DRC and Uganda [21][22].

Former CDC Director Tom Frieden characterized the combined effect as a "1-2-3 punch to global health architecture" [21]. Two former USAID officials told CNN that many of the personnel with outbreak response experience in Central Africa — as well as their relationships with local health officials — were lost when USAID was dismantled. "Almost everyone on the USAID team that worked on the most recent previous Ebola outbreak in Uganda" was fired, the report stated [21].

Josh Michaud, associate director for global and public health policy at KFF, said: "When you add up all of those elements, it's hard to see how there could not have been an effect on the surveillance and response capacities in these countries" [21].

The administration has pushed back against the framing that funding cuts caused the outbreak. The State Department's announcement of 50 response clinics and the CDC's mobilization of international response teams indicate continued U.S. engagement [20][23]. PolitiFact reported that while USAID funding cuts preceded the outbreak, the causal relationship between those cuts and the outbreak's spread involves multiple confounding factors, including the inherent unpredictability of zoonotic spillover events [22].

The administration also plans to redirect $2 billion in funding originally intended for global health programs to cover the cost of closing USAID, a plan that includes $647 million in funding reductions for global health security [21].

Infrastructure vs. Emergency Response: A Recurring Debate

The pattern of Ebola outbreaks in Central and East Africa — this is DRC's 17th since 1976 — has prompted a longstanding debate about whether the global response architecture is fundamentally misaligned [8].

Critics argue that repeated emergencies reflect a failure to build durable local health infrastructure. A 2016 study in BMC Public Health found that health systems in Guinea, Liberia, and Sierra Leone had "several essential health-system functions not performing well" when Ebola arrived, including "weak or non-existent national disease surveillance systems" [24]. A PBS investigation found that nearly $120 million in aid over 11 years in Sierra Leone helped establish "an entire parallel health system" for HIV/AIDS patients, while broader health infrastructure received comparatively little investment [25].

The structural incentive is clear: donor agencies have historically earmarked funds for specific diseases — HIV, malaria, tuberculosis — rather than for the general health systems that would detect and contain any outbreak. The result, critics contend, is a cycle in which emergency funding surges during crises and recedes afterward, leaving the underlying vulnerabilities intact [24][25].

Defenders of the current model point out that disease-specific programs have achieved measurable results: millions of lives saved through antiretroviral therapy, bed net distribution, and vaccination campaigns. The challenge, they argue, is not that vertical programs are wrong but that horizontal health system strengthening has been underfunded alongside them.

African leaders are increasingly framing the solution in terms of "health sovereignty." At the 2026 World Health Assembly, which opened under the shadow of the Ebola and hantavirus outbreaks, several heads of state called for systems financed and managed with far less reliance on external aid [19][26].

Travel Restrictions: Evidence and Trade-offs

The U.S. imposed entry restrictions on May 18, barring foreign travelers who have been in the DRC, Uganda, or South Sudan within the past 21 days. The ban does not apply to U.S. citizens or permanent residents and is set for an initial 30-day period [27][28].

Uganda and DRC have sharply reduced border activity, permitting only essential traffic for four weeks. Public passenger transport — buses, flights, and Semliki River ferries — has been halted, though goods and food transportation remain exempt [29].

Africa CDC has opposed broad travel restrictions. Director-General Kaseya argued that "the fastest path to protecting all countries in the world is to aggressively support outbreak control at the source," and that blanket bans "create fear, damage economies, discourage transparency, complicate humanitarian and health operations, and divert movement toward informal and unmonitored routes" [30].

The WHO IHR Emergency Committee aligned with this position, recommending against flight suspensions or entry denials while calling for exit screening at affected-nation borders [9]. The committee's recommendations include mandatory questionnaires, temperature checks, and risk assessments for departing travelers, and a prohibition on international travel for suspected or probable cases unless medically evacuated [9].

The empirical record from 2014–2016 is mixed. Research published in The Lancet found that travel restrictions during the West Africa outbreak delayed the arrival of health workers and supplies more than they slowed viral spread, which primarily occurred through local transmission chains rather than international air travel. COVID-19 later demonstrated that border closures could buy time but not prevent eventual spread of highly transmissible pathogens [30].

Who Is Most at Risk

The outbreak disproportionately affects several sub-populations. Healthcare workers have already died in this outbreak and face ongoing risk, particularly where protective equipment is scarce [6][17]. The IRC reported that in some DRC health facilities, "health workers have almost no protective equipment left" [17].

Women and girls face elevated vulnerability during Ebola outbreaks. The IRC noted that access to prenatal care diminishes and risks of gender-based violence increase as healthcare systems become overwhelmed [17].

Cross-border traders and miners who move between Ituri and neighboring countries represent a key transmission vector. The outbreak region's role as a mining hub means that migrant workers may carry the virus to distant communities before symptoms appear [11][14].

Internally displaced persons — numbering in the hundreds of thousands in Ituri alone — face compounded risks. Displacement camps often lack adequate sanitation, healthcare access, and the ability to implement isolation protocols. Conflict has intensified in the region since late 2025, making humanitarian access difficult [10][17].

Rural communities without hospital access may experience the highest case fatality rates because they cannot receive even basic supportive care. The WHO noted that community deaths occurring "outside formal healthcare systems" have been a significant factor in the outbreak's spread, as these deaths often occur without diagnosis and without the safe burial practices that prevent further transmission [14].

What Comes Next

The outbreak is still accelerating. Confirmed cases rose from 8 on May 15 to 88 by May 23 — a tenfold increase in eight days [3][7]. The true number of infections is almost certainly higher, given the gap between suspected and confirmed case counts.

Without a vaccine, the response depends entirely on the fundamentals: finding cases, tracing contacts, isolating the sick, and safely burying the dead. Those fundamentals require funding, personnel, and community trust — all of which are under strain.

The IHR Emergency Committee's temporary recommendations provide a framework, but their implementation depends on resources that have not yet materialized at the scale Africa CDC considers necessary. The $319 million the agency has requested dwarfs the $30 million it has received [14]. The coming weeks will determine whether the international community closes that gap before the outbreak reaches the 10 countries now on alert.